Topiramate therapy for paroxysmal kinesigenic choreoathetosis.
We observed the clinical efficacy of topiramate for paroxysmal kinesigenic choreoathetosis (PKC). Topiramate was administered as a monotherapy with titrated dosages to 8 patients with PKC. Target daily dose of topiramate was 100 to 200 mg; the follow-up period ranged from 8 months to 2 years. All of the patients became attack-free, and side effects were mild. The results show that topiramate is effective as a monotherapy for treating patients with PKC. The response to topiramate indicates that the disease may be caused by an ion channel defect.
Huang
Yuan-Gui
YG
The Department of Neurology, Xijing Hospital, the Fourth Military Medical University, Shaanxi, People's Republic of China.
Chen
Yun-Chun
YC
Du
Fang
F
Li
Rui
R
Xu
Ge-Lin
GL
Jiang
Wen
W
Huang
Jing
J
D000293:Adolescent; D000328:Adult; D000927:Anticonvulsants / Q000627:therapeutic use*; D001264:Athetosis / Q000150:complications* / Q000188:drug therapy*; D002648:Child; D002819:Chorea / Q000150:complications* / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D005260:Female; D005500:Follow-Up Studies; D005632:Fructose / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D000077236:Topiramate; D016896:Treatment Outcome
D000927:Anticonvulsants; D000077236:Topiramate; D005632:Fructose